Qitian Gene was awarded tens of millions of yuan in Series A financing, and the joint venture invested independently.
On April 8th, recently, Qitian Gene Biotechnology Co., Ltd. ("Qi Tian Gene") announced the completion of the A round of tens of millions of financing, with exclusive investment by Xie Li Investment. After this round of financing, Qitian Gene will continue to improve its production facilities, expand production capacity, accelerate the promotion of market access, and continue to carry out team building and introduce outstanding talents to support the rapid growth of business. Qitian Gene specializes in the development and application of isothermal nucleic acid amplification technology. It mainly develops detection kits, detection instruments and technical services for molecular detection. It is a scientific and technological enterprise integrating R&D, production, sales and service. Products are mainly for public health (inspection and quarantine airport ports, disease control centers, food safety, etc.), medical fields (hospitals, community medical, etc.), scientific research (colleges, colleges, universities, enterprises, etc.), public safety (event) Prevention and control, military biochemical prevention and control, etc., ecological environment (transgenic detection, species identification, environmental microorganisms, etc.). The company was established in Wuxi in 2012. Up to now, the company has completed the completion of GMP large-scale production base, and passed the clean performance test of Wuxi City Drug Inspection Institute (100,000, 10,000), following the 13th Five-Year Plan in 2017. The special project (the sub-project leader unit, three projects) has also won the 13th Five-Year National Major Project (Task Unit, Four Projects) in 2018. At the same time, the company has completed the Angel Wheel and the A round of financing from the joint investment. . The company's main products are divided into kits, instruments and technical services. Among them, RAA products have the advantages of isothermal, fast, high accuracy, strong specificity and high sensitivity, which is easier and faster than the existing PCR technology. The reagent product can be made into the form of lyophilized powder, which is convenient for transportation and storage. The detection and operation process can be carried out at normal temperature, and the operation is convenient, so that molecular detection can realize one-step method. The supporting testing instruments are made into portable miniaturization, which can realize the detection of infectious diseases, pathogenic food-borne microorganisms, genetic diseases, gene mutation points and rapid detection of ctDNA. It can be applied to the rapid detection of food safety and the immediate infection of major infectious diseases. Testing and diagnosis, remote areas and field testing, hospital POCT and precision medicine . With the increasing scale of the company, the company has provided products and services to the local inspection and quarantine bureaus, disease prevention and control centers, etc., and has maintained a good long-term cooperative relationship. Xie Li Investment believes that as a new generation of molecular diagnostic technology, Qitian's RAA isothermal molecular amplification technology with independent intellectual property rights is expected to be widely used in clinical diagnosis, inspection and quarantine, species identification, food safety and other fields. Qitian Gene masters the complete scale production capacity of this technology from upstream enzymes, protein raw materials to lyophilization reagents and detection equipments. It has outstanding competitive advantages in quality control and cost, and is expected to become the field of isothermal amplification molecular detection. Leading company. Qi Zhihong, founder of Qitian Gene, said that after the completion of this financing, the company will continue to strengthen team building. Talents are the foundation of the company's development, and will continue to improve product production facilities. Capacity is the last word; at the same time, the company will accelerate market expansion. Speed, truly promote the application of a new generation of molecular diagnostic technology in various fields, Qitian gene will accelerate to become the leading enterprise in the field of isothermal amplification molecular detection. Anesthesia Medical Co., Ltd. , https://www.honestymed.com